Generic Rebetol meeting
Three Rivers Pharmaceuticals meets with FDA Chief Counsel Daniel Troy to discuss "labeling issues" for generic version of Schering-Plough's Rebetol (ribavirin) June 24. Three Rivers expects 2003 launch for the generic...
You may also be interested in...
Three Rivers Pharmaceuticals is amending its ribavirin ANDA to remove references to an 800 mg dose appearing in Schering-Plough's Rebetol labeling
Increasing clinical trial complexity goes hand in hand with increased reliance on advanced-analysis software. Raj Indupuri of eClinical Solutions believes the company's product will lead this emerging market.
Merck KGaA’s short-course oral MS therapy Mavenclad may gain a boost from new data suggesting its use does not affect the beneficial response of patients to COVID-19 vaccines, as the research and manufacturing reagents and solutions business unit of the diversified big pharma reported a strong first quarter due to pandemic-related demand.